Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accumulated Expenses (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Accumulated Expenses data on record, last reported at $2.1 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 12.0% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $2.1 million, up 12.0%, while the annual FY2024 figure was $2.1 million, 314.6% up from the prior year.
  • Accumulated Expenses reached $2.1 million in Q3 2025 per RANI's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.4 million in Q3 2022 and bottomed at $500000.0 in Q4 2023.
  • Average Accumulated Expenses over 5 years is $2.6 million, with a median of $2.4 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: crashed 78.71% in 2023, then soared 314.6% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $1.4 million in 2021, then skyrocketed by 63.81% to $2.3 million in 2022, then plummeted by 78.71% to $500000.0 in 2023, then skyrocketed by 314.6% to $2.1 million in 2024, then rose by 0.87% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $2.1 million in Q3 2025, $2.6 million in Q2 2025, and $2.3 million in Q1 2025.